MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 10.03.2026
Homology Medicines EV 2011-2026 | FIXX
EV Jährlich Homology Medicines
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -28.5 M | 8.69 M | 92.8 M | 127 M | 362 M | 672 M | 604 M | 39.2 M | 24.1 M | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 672 M | -28.5 M | 211 M |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
9.45 M | $ 0.89 | - | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
3.33 B | $ 22.35 | 0.68 % | $ 3.7 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | USA |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
-4.91 B | $ 103.69 | 2.08 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
259 M | $ 1.48 | -0.67 % | $ 235 M | France |
 |
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 3.65 | 22.48 % | $ 6.01 M |  Israel |
 |
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
540 M | $ 4.08 | 0.74 % | $ 436 M | USA |
 |
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.2 M | - | 17.91 % | $ 11.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 22.65 | 1.25 % | $ 2.88 B | USA |
 |
Edesa Biotech
EDSA
|
6.91 M | $ 16.23 | 2.08 % | $ 51.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
Athira Pharma
ATHA
|
-4.92 M | - | - | $ 269 M | USA |
 |
Alpine Immune Sciences
ALPN
|
363 M | - | - | $ 2.17 B | USA |
 |
Avenue Therapeutics
ATXI
|
-1.76 M | - | -52.27 % | $ 4.45 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.02 M | - | 10.36 % | $ 9.8 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
629 M | $ 1.42 | 0.71 % | $ 378 M | Britain |
 |
AVROBIO
AVRO
|
-35.4 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | Britain |
 |
Evogene Ltd.
EVGN
|
-4.88 M | $ 0.79 | 4.79 % | $ 27.9 M | Israel |
 |
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | USA |
 |
Exelixis
EXEL
|
11.9 B | $ 45.0 | 0.69 % | $ 12.2 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Завод ДИОД
DIOD
|
3.14 B | - | - | - | Russia |